Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Long-Term Deferred Tax (2022 - 2025)

Historic Long-Term Deferred Tax for Lexaria Bioscience (LEXX) over the last 4 years, with Q3 2025 value amounting to $13.4 million.

  • Lexaria Bioscience's Long-Term Deferred Tax rose 2498.47% to $13.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was $13.4 million, marking a year-over-year increase of 2498.47%. This contributed to the annual value of $13.4 million for FY2025, which is 2498.47% up from last year.
  • Latest data reveals that Lexaria Bioscience reported Long-Term Deferred Tax of $13.4 million as of Q3 2025, which was up 2498.47% from $10.7 million recorded in Q3 2024.
  • Over the past 5 years, Lexaria Bioscience's Long-Term Deferred Tax peaked at $13.4 million during Q3 2025, and registered a low of $7.9 million during Q3 2022.
  • Its 4-year average for Long-Term Deferred Tax is $10.4 million, with a median of $10.2 million in 2023.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first surged by 1200.77% in 2024, then soared by 2498.47% in 2025.
  • Quarter analysis of 4 years shows Lexaria Bioscience's Long-Term Deferred Tax stood at $7.9 million in 2022, then grew by 21.81% to $9.6 million in 2023, then grew by 12.01% to $10.7 million in 2024, then grew by 24.98% to $13.4 million in 2025.
  • Its Long-Term Deferred Tax was $13.4 million in Q3 2025, compared to $10.7 million in Q3 2024 and $9.6 million in Q3 2023.